| Literature DB >> 32340247 |
Eunseon Jeong1, Yeni Lim2, Kyeong Jin Kim3, Hyeon-Hui Ki4, Doheon Lee4,5, Jaehyun Suh6, Seung-Ho So6, Oran Kwon2, Ji Yeon Kim1,3.
Abstract
Red ginseng has been widely used in health-promoting supplements in Asia and is becoming increasingly popular in Western countries. However, its therapeutic mechanisms against most diseases have not been clearly elucidated. The aim of the present study was to provide the biological mechanisms of redEntities:
Keywords: Panax ginseng; metabolic disease; network analysis; red ginseng; systems biology
Year: 2020 PMID: 32340247 PMCID: PMC7221703 DOI: 10.3390/molecules25081967
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structural formulae of components in red ginseng with their target genes.
Figure 2Top 10 enriched pathways of Panax ginseng in metabolic diseases. (a) Menopause symptoms (b) Blood circulation (c) Hyperlipidemia (d) Diabetes mellitus. The y-axis shows the significantly enriched pathways of the targets, and the x-axis shows the enrichment scores of the terms (p < 0.05).
Figure 3Top 10 enriched pathways of red ginseng in metabolic diseases. (a) Menopause symptoms. (b) Blood circulation. (c) Hyperlipidemia. (d) Diabetes mellitus. The y-axis shows the significantly enriched pathways of the targets and the x-axis shows the enrichment scores of the terms (p < 0.05).
Figure 4Target-pathway network. (a) Panax ginseng and (b) Red ginseng. Targets (green) and pathways (blue). Cytoscape file was included as supplementary information (Figures S1 and S2).
Figure 5(a) Herb-component-target/pathway-phenotype network. (b) Component-target-pathway network of red ginseng. Components (red), targets (green), and pathways (blue). Cytoscape file was included as supplementary information (Figure S3).
Top 10 targets of red ginseng in metabolic diseases.
| No. | Menopausal Women’s Symptoms | Blood Circulation | Hyperlipidemia | Diabetes Mellitus |
|---|---|---|---|---|
| 1 | TNF | MAPK1 | PLCG1 | PLCG1 |
| 2 | AKT1 | TNF | IRAK4 | IRAK4 |
| 3 | FOS | MAPK3 | MAPK9 | MAPK9 |
| 4 | JUN | NFKBIA | - | - |
| 5 | MAPK1 | IL6 | - | - |
| 6 | MAPK3 | AKT1 | - | - |
| 7 | NFKBIA | FOS | - | - |
| 8 | CREB1 | TGFB1 | - | - |
| 9 | IL6 | ROCK1 | - | - |
| 10 | IRAK1 | BCL2 | - | - |
ATT, serine/threonine-specific protein kinas; BCL2, B-cell lymphoma 2; CREB, cAMP response element-binding protein; FOS, fos proto-oncogene, AP-1 transcription factor subunit; IL, interleukin; IRAK, interleukin receptor-associated kinase; JUN, jun proto-oncogene, AP-1 transcription factor subunit; MAPK, mitogen-activated protein kinase; NFKBIA, NFKB Inhibitor Alpha; PLCG1, phospholipase C, gamma 1; ROCK1, rho associated coiled-coil containing protein kinase 1; TGFB1, transforming growth factor b 1; TNF, tumor necrosis factor alpha.